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Conclusions
Statistical models, that can predict the risk of early HCC recurrence after resection, have been developed, extensively validated and shown to be applicable in the international setting. Such models will be valuable in guiding surveillance follow-up and in the design of post-resection adjuvant therapy trials.
LAY SUMMARY
The most effective treatment of cancer that starts in the liver (hepatocellular carcinoma) is surgical removal of the tumour but there is often recurrence. In this large international study, we develop a statistical method that allows clinicians to estimate the risk of recurrence in an individual patient. This facility enhances communication with the patient about the likely success of the treatment and will help in designing clinical trials that aim to find drugs that decrease the risk of recurrence. However, tumour recurrence is a major post-operative complication and is generally classified into early or late recurrence by using 2 years as the cut-off. (5, 6) Early recurrence (i.e. within 2 years of resection) accounts for more than 70% of tumour recurrence and is assumed to represent 'true recurrence' whereas after this period "recurrences" are assumed to be largely accounted for by 'de novo' tumours. (7) The 2-year recurrence-free survival (RFS) is about 50% and 30% among and those with BCLC 0 or A tumours, respectively. (7) (8) (9) Identification of patients after potentially curative surgery who are at high risk of recurrence allows clinicians to provide appropriate surveillance so as to detect recurrent HCC at its earliest stage, when curative therapy may still be feasible.
Curative therapy offers much more favourable long-term survival than palliative therapy among patients with recurrent HCC. (3, 10, 11) Patients at high risk of early recurrence are potential candidates for clinical trials of adjuvant therapy although there is no standard of care for adjuvant therapy for surgically treated HCC patients. (6, 12) (13) (14) (15) Currently, there is no consensus as to the optimal tool for risk stratification and this may partially contribute to failure of clinical trials of adjuvant therapy due to suboptimal patient selection. Except for the American Joint Committee on Cancer (AJCC) Tumour-NodeMetastasis (TNM), the majority of HCC staging systems are not derived from surgically managed patients. Their prognostic performances on classifying post-operative early recurrence have not been fully evaluated. A few models including the Singapore Liver Cancer Recurrence (SLICER) score, the Korean model, Surgery-Specific Cancer of the Liver Italian Program (SS-CLIP), have been developed specifically to detect tumour recurrence after surgical resection but none of them have been externally validated. (8, 9, 16) . Moreover, microvascular invasion is an important component of AJCC TNM, SLICER, SS-CLIP and Korean models, but only can be evaluated pathologically in the resected specimen after operation. A prognostic model that only requires parameters that are available pre-operatively may help surgeons to better select surgical candidates.
In this study, we employed large cohorts from different countries to develop and validate prognostic models for surgically treated HCC patients based on readily accessible clinical and pathological parameters on order to predict early recurrence. Two models were developed:
One included parameters available before surgery so as to allow prediction of early recurrence pre-operatively, and a second that included parameters available only after resection to give a more accurate prediction.
Patients and methods
This analysis was reported according to the TRIPOD (Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) guidelines(17).
Patients
In this international retrospective cohort study, a total of 3903 surgically treated HCC patients from 6 centres in different countries were accrued. These centres comprise Hong Kong (the Chinese University of Hong Kong), mainland China (the First Affiliated Hospital of Wenzhou Medical University, Wenzhou; Affiliated Tumour Hospital of Guangxi Medical University, Nanning), Italy (S.Orsola-Malpighi Hospital, University of Bologna and Gastrointestinal Surgery, Istituto Nazionale Tumori, Milan), Japan (Ogaki Municipal Hospital), and the United States (personal experience Sasan Roayaie, New York). All centres fulfilled ethical requirements (including informed consent) according to local practice and it is our understanding that such studies do not require formal protocol approval. Inclusion requirements were that the patients underwent surgical resection of HCC with curative intent.
Patients who underwent resection for tumour rupture were excluded. All resections were undertaken after the year 2000 except for the Japanese cohort where patients were recruited between 1990 and 2014. There was no statistically significant difference in survival or recurrence rates between those treated before and after the year 2000. Table 1 summarizes baseline characteristics of the patient cohorts. Patients with missing data were excluded from the analysis.
The pre-operative and post-operative ERASL models were built on the Hong Kong dataset (dates 2001-2012) and then internally validated on a similar population from Hong Kong (dates 2013-2015). We then validated the models externally on datasets from mainland China, Italy, Japan and the United States. The criteria for surgical resection in Eastern centres (Hong Kong, mainland China and Japan) included: good liver function indicated by a 15-min ICG retention rate of <30% (Hong Kong and Japan) or Child-Pugh A with presence of appropriate residual liver volume determined by volumetric computed tomography and/or magnetic resonance imaging (mainland China); a single HCC, or not more than 3 HCCs, located in the same segment; less than 85 years of age (<75 years in Wenzhou); and absence of extrahepatic metastasis. In Italy(18), and the United States, a personalized approach was undertaken based on multidisciplinary discussion.
All clinical and laboratory parameters were collected and reviewed from patients' records.
The Albumin-Bilirubin (ALBI) score was computed by the formula, −0.085× (albumin g/l) + 0.66×log (bilirubin µmol/l).(19) Patients were stratified into three groups according to previously described cut-offs resulting in three grades: ALBI grade 1 (≤−2.60), grade 2 (>−2.60 to −1.39) and grade 3 (>−1.39).(19) Macrovascular invasion was defined as vascular invasion of large vessels detectable radiologically, whereas microvascular invasion was vascular invasion of small vessels only identifiable histologically. There was no microvascular invasion data available in the Nanning cohort, hence this cohort was used for validation of the pre-operative model only. Patients in the Hong Kong cohort were classified according to 7th edition of AJCC TNM, Korean model (including 5 parameters: gender, tumour volume, microvascular invasion, serum albumin and platelet count) and SLICER score (using 8 parameters: symptomatic, cirrhotic background, Child-Pugh grade, surgical resection margin distance, tumour size, tumour number, vascular invasion, and preoperative serum alpha fetoprotein AFP). (8, 9) After tumour resection, all patients were followed up according to institutional practice including clinical assessment serum AFP 6-monthly and ultrasound or contrast-enhanced computed tomography every 6 to 12 months. RFS was defined as the time from date of curative surgery to the time of recurrence. Patients with no recurrent disease were censored at the last time at which they were known to be recurrence free. Those dying within 90 days of surgery were not excluded from the analysis. The 90-day mortality rate was 0.6% (Hong Kong derivation cohort), 0.7% (Hong Kong internal validation cohort), 1.5% (Japan), 7.7% (the United States), 0% (Wenzhou, China), 0.9% (Nanning, China) and 2.7% (Italy).
Statistical analyses
All statistical analyses were performed in R version 3. Model discrimination was assessed via the "regression on the prognostic index (PI)" approach (20), also known as the "calibration slope". The regression coefficient on the risk score in the validation sets was estimated and compared to that of the derivation set, which is by construction exactly 1. If the validation set coefficients equals to 1, <1 or >1, they reflect as good as, poorer or better discrimination respectively in relation to the derivation set.
Model discrimination in the derivation and validation sets was also measured by the Harrell's Models were calibrated using calibration plots and comparing model-predicted versus observed survival curves.
Calibration plots were applied to the derivation and validation sets. Estimates of predicted versus observed values were generated via bootstrapping (with 200 resampling). In order to obtain a continuous calibration plot for a specific survival time, regression-spline interpolations(23, 24) were used to generate a continuous observed survival probability. The resulting plot was also "optimism-corrected" by a method described by Harrell et al (25).
Model-predicted mean survival curves were generated by applying fractional polynomial regression to approximate the log baseline cumulative hazard function as a smooth function of time (20). Model-predicted versus KM estimates was then plotted according to each risk group in the derivation and validation sets.
Results

Construction of the model predicting early recurrence
In the derivation cohort, 451 patients receiving curative surgery between 2001 and 2012 were recruited after excluding 44 patients who were complicated by tumour rupture before operation. There were only two patients with missing data on at least one of the variables.
ALBI grade 2 and ALBI grade 3 were group together due to low sample size in the latter. One hundred and sixty-two patients (35.9%) developed recurrence within 2 years of surgery.
Among 18 clinicopathological parameters analysed, 12 were found to be potentially relevant with p<0.2 in the univariable Cox regression analysis (Supplementary table 1) . Four of these, namely positive resection margin, ALT, ALP and INR, had to be excluded because they were not available in all of the external validation cohorts. Two parameters, namely (intraoperative blood loss and microvascular invasion) were only recorded after the operation and hence excluded in the multivariable analysis for establishing the pre-operative model, whereas all 8 parameters were employed for building the post-operative model. By the stepwise multivariable analysis, independent parameters were identified for both models (Table 2) . We did not detect any significant violation of the proportional hazard assumption, assessed by scaled Schoenfeld residuals on functions of time.
The pre-operative model, Early Recurrence After Surgery for Liver tumour (ERASL-pre) score, was constructed; its formula shown in Table 2 . The RFS of an individual patient with a particular ERASL-pre score can be estimated by applying a previously described formula (Supplementary table 2 Similarly, the post-operative model, ERASL-post, was built according to the formula for score shown in Table 2 . As in ERASL-pre, the RFS of an individual patient with a particular ERASL-post score can be estimated (Supplementary (Table 3 ; Fig. 1B) . Similarly, patients from the independent external validation cohorts from five centres (after exclusion of patients with incomplete data on predictor parameters), Japan (n=582), the United States (n=548);
Wenzhou, China (n=98); Nanning, China (n=1198); and Italy (n=742), could be also categorized into three separate risk groups by the ERASL-pre model (Fig. 1C-F) (Table 3) .
Likewise, the ERASL-post model subdivided patients from the internal and external validation cohorts into three distinct risk groups (Fig. 2C-F) (Table 4) .
Assessing model discrimination
Overall, the regression coefficient on the ERASL-pre and post scores showed good discrimination relative to the derivation set across validation cohorts (coefficient figures ranging from 0.70 to 1.21) although discrimination was less good in the Italian cohort (ERASL-pre: 0.59, ERASL-post: 0.65).
Similarly the discriminatory performance of the models was compared via Harrell's c-index,
and tdAUC as shown in Table 5 . Both models showed similar performance in the derivation and internal validation sets. In the external validation cohorts, good discrimination was also observed, although there was a slight deterioration in the measurement figures, which was most pronounced in the Italian cohort.
The discriminatory performance of both ERASL models exceeded those of AJCC TNM, the Korean model and the SLICER score in predicting early recurrence (Table 5) . By including microvascular invasion, ERASL-post showed a better performance than ERASL-pre.
Calibration
The calibration plots showed an overall good agreement between the predictions made by the Nevertheless, despite some of discrepancies between predicted and KM estimates in some of the risk groups, the stratification of each of the cohorts into three groups according to risk was maintained.
KM survival plots according for the ERASL-pre and post risk groups involving the entire cohort are shown in Supplementary figure 4.
Discussion
Two models (ERASL-pre and ERASL-post) that enable risk assessment of early recurrence before and after resection have been derived and validated in a large international multicentre study of surgically-treated HCC patients. Although they were derived from a hepatitis B prevalent region (Hong Kong), their application was generalizable to regions with predominant hepatitis C (Japan and Italy) or mixed aetiologies (the United States). Supplementary Fig. 4) .
Correspondingly, the ERASL-post also identified a high-risk group comprising 12.3% of patients among the entire cohort with 73.9% chance of early recurrence ( Supplementary Fig.   4 ). Both models are clinically relevant because they allow the identification of a small, but potentially manageable, portion of patients at high risk in the development of early recurrence.
Although it may not be considered appropriate to exclude those patients at high-risk of early recurrence from curative surgery, more intensive surveillance might be offered and they would be candidates for clinical trials of adjuvant therapy. The ERASL models are also reliable as they are the first models designed to predict early recurrence that have been externally validated in different geographic regions and with different etiological factors.
Despite, a minor degree of discrepancy between predicted and KM estimates (Supplementary figure 2 and 3) , the stratification of each of the cohorts into three groups according to risk was There are limitations to our study. Our models, at first sight, may appear complex and difficult to apply at the bedside, but our simple online calculator overcomes this problem. Although there might be some variations in tumour size depending on the method of assessment, the discrepancies are unlikely to be clinically significant.
In summary, tumour recurrence after curative surgery for HCC is a serious and common complication. Our ERASL models are clinically relevant, externally validated and offer powerful tools to predict early recurrence. Further prospective studies are required to explore the clinical applicability of ERASL models in patient allocation for more frequent follow-up and clinical trials for adjuvant therapy. We are currently developing a more general prognostic model that is applicable to both early and late recurrence, and the performance of the ERASL models is being prospectively evaluated in an adjuvant clinical trial. Macrovascular invasion 38 (8.4), n=451 9 (6.9), n=130 44 (7.4), n=599 186 (28.6), n=651 9 (9.0), n=100 205 (17.0), n=1203 0 (0), n=742
Clinical outcome
Recurrence with 2 years, n( AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; CI, confidence interval; IQR, interquartile range; RFS, recurrence-free survival; SD, standard deviation. Mean (standard deviation) presented for normally distributed continuous variables, while median (interquartile range) was given to those with non-normally distributed continuous variable. hazard ratios (with p-values) and percentage RFS at two years, are reported in Table 3 . Table 4 . 
